Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Vitiligo: Pathogenesis, clinical features, and diagnosis

Pearl E Grimes, MD
Section Editor
Hensin Tsao, MD, PhD
Deputy Editor
Rosamaria Corona, MD, DSc


Vitiligo is a relatively common acquired disorder of pigmentation characterized by the development of well-defined white macules on the skin. Biopsies of lesional skin reveal a loss of epidermal melanocytes [1-4]. Lesions may occur in a localized or generalized distribution and may coalesce into large, depigmented areas. Given the contrast between the white areas and normal skin, the disease is most disfiguring in darker skin types and has a profound impact on the quality of life of both children and adults [5,6]. Patients with vitiligo often experience stigmatization, social isolation, and low self-esteem [7-10].

This topic will review the pathogenesis, classification, clinical manifestations, and diagnosis of vitiligo. The management and prognosis of vitiligo are discussed separately. Other pigmentation disorders are also discussed separately.

(See "Vitiligo: Management and prognosis".)

(See "Acquired hypopigmentation disorders other than vitiligo".)

(See "Approach to the patient with hyperpigmentation disorders".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jul 5, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Zedan H, Abdel-Motaleb AA, Kassem NM, et al. Low glutathione peroxidase activity levels in patients with vitiligo. J Cutan Med Surg 2015; 19:144.
  2. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet 2015; 386:74.
  3. Mohammed GF, Gomaa AH, Al-Dhubaibi MS. Highlights in pathogenesis of vitiligo. World J Clin Cases 2015; 3:221.
  4. Ortonne J-P, Passeron T. Vitiligo and other disorders of hypopigmentation. In: Dermatology, 3rd ed, Boloniga JL, Jorizzo JL, Schaffer JV (Eds), Elsevier, Philadelphia 2012. p.1023.
  5. Krüger C, Schallreuter KU. Stigmatisation, Avoidance Behaviour and Difficulties in Coping are Common Among Adult Patients with Vitiligo. Acta Derm Venereol 2015; 95:553.
  6. Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with vitiligo. Pediatr Dermatol 2014; 31:309.
  7. Robins A. Biological Perspectives on Human Pigmentation, Cambridge University Press, Cambridge, UK 2005. Vol 7.
  8. Grimes PE. Disorders of pigmentation. In: ACP Medicine, Dale DC, Federman DD (Eds), WebMD Scientific American Medicine, New York 2012. p.526.
  9. Porter J. The psychological effects of vitiligo: Response to impaired appearance. In: Vitiligo, Hann SK, Nordlund JJ (Eds), Blackwell Science, Oxford, UK 2000. p.97.
  10. Daniel BS, Wittal R. Vitiligo treatment update. Australas J Dermatol 2015; 56:85.
  11. Ezzedine K, Lim HW, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 2012; 25:E1.
  12. Yaghoobi R, Omidian M, Bagherani N. Vitiligo: a review of the published work. J Dermatol 2011; 38:419.
  13. Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003; 16:208.
  14. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011; 65:473.
  15. Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol 2012; 51:1206.
  16. Lee H, Lee MH, Lee DY, et al. Prevalence of vitiligo and associated comorbidities in Korea. Yonsei Med J 2015; 56:719.
  17. Grimes PE, Billips M. Childhood vitiligo: Clinical spectrum and therapeutic approaches. In: Vitiligo, Hann SK, Nordlund JJ (Eds), Blackwell Science, Oxford, UK 2000. p.61.
  18. Grimes PE. New insights and new therapies in vitiligo. JAMA 2005; 293:730.
  19. Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001; 2:167.
  20. Le Poole IC, Das PK, van den Wijngaard RM, et al. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993; 2:145.
  21. Bhatia PS, Mohan L, Pandey ON, et al. Genetic nature of vitiligo. J Dermatol Sci 1992; 4:180.
  22. Majumder PP, Das SK, Li CC. A genetical model for vitiligo. Am J Hum Genet 1988; 43:119.
  23. Nath SK, Majumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Am J Hum Genet 1994; 55:981.
  24. Fain PR, Gowan K, LaBerge GS, et al. A genomewide screen for generalized vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci. Am J Hum Genet 2003; 72:1560.
  25. Czajkowski R, Męcińska-Jundziłł K. Current aspects of vitiligo genetics. Postepy Dermatol Alergol 2014; 31:247.
  26. Thorsby E, Lie BA. HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms. Transpl Immunol 2005; 14:175.
  27. Orecchia G, Perfetti L, Malagoli P, et al. Vitiligo is associated with a significant increase in HLA-A30, Cw6 and DQw3 and a decrease in C4AQ0 in northern Italian patients. Dermatology 1992; 185:123.
  28. Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med 2010; 362:1686.
  29. Quan C, Ren YQ, Xiang LH, et al. Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet 2010; 42:614.
  30. Jin Y, Birlea SA, Fain PR, et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet 2012; 44:676.
  31. Tang XF, Zhang Z, Hu DY, et al. Association analyses identify three susceptibility Loci for vitiligo in the Chinese Han population. J Invest Dermatol 2013; 133:403.
  32. Chen JJ, Huang W, Gui JP, et al. A novel linkage to generalized vitiligo on 4q13-q21 identified in a genomewide linkage analysis of Chinese families. Am J Hum Genet 2005; 76:1057.
  33. Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007; 356:1216.
  34. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38:647.
  35. Boissy RE, Nordlund JJ. Molecular basis of congenital hypopigmentary disorders in humans: a review. Pigment Cell Res 1997; 10:12.
  36. Betterle C, Caretto A, De Zio A, et al. Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo. Dermatologica 1985; 171:419.
  37. Grimes PE, Halder RM, Jones C, et al. Autoantibodies and their clinical significance in a black vitiligo population. Arch Dermatol 1983; 119:300.
  38. Naughton GK, Eisinger M, Bystryn JC. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983; 81:540.
  39. Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90:783.
  40. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16:90.
  41. Gilhar A, Pillar T, Eidelman S, Etzioni A. Vitiligo and idiopathic guttate hypomelanosis. Repigmentation of skin following engraftment onto nude mice. Arch Dermatol 1989; 125:1363.
  42. Ghoneum M, Grimes PE, Gill G, Kelly AP. Natural cell-mediated cytotoxicity in vitiligo. J Am Acad Dermatol 1987; 17:600.
  43. Ogg GS, Rod Dunbar P, Romero P, et al. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998; 188:1203.
  44. Richmond JM, Frisoli ML, Harris JE. Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol 2013; 25:676.
  45. van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129:2220.
  46. Mandelcorn-Monson RL, Shear NH, Yau E, et al. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 2003; 121:550.
  47. Taieb A, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 2013; 168:5.
  48. Dell'anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006; 19:406.
  49. Dell'Anna ML, Maresca V, Briganti S, et al. Mitochondrial impairment in peripheral blood mononuclear cells during the active phase of vitiligo. J Invest Dermatol 2001; 117:908.
  50. Picardo M, Grammatico P, Roccella F, et al. Imbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma. J Invest Dermatol 1996; 107:322.
  51. Morrone A, Picardo M, de Luca C, et al. Catecholamines and vitiligo. Pigment Cell Res 1992; 5:65.
  52. Hasse S, Gibbons NC, Rokos H, et al. Perturbed 6-tetrahydrobiopterin recycling via decreased dihydropteridine reductase in vitiligo: more evidence for H2O2 stress. J Invest Dermatol 2004; 122:307.
  53. Schallreuter KU, Wood JM, Lemke KR, Levenig C. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 1995; 190:223.
  54. Nordlund JJ. The significance of depigmentation. Pigment Cell Res 1992; Suppl 2:237.
  55. Nelhaus G. Acquired unilateral vitiligo and poliosis of the head and subacute encephalitis with partial recovery. Neurology 1970; 20:965.
  56. Al'Abadie MS, Warren MA, Bleehen SS, Gawkrodger DJ. Morphologic observations on the dermal nerves in vitiligo: an ultrastructural study. Int J Dermatol 1995; 34:837.
  57. Al'Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994; 131:160.
  58. Mozzanica N, Villa ML, Foppa S, et al. Plasma alpha-melanocyte-stimulating hormone, beta-endorphin, met-enkephalin, and natural killer cell activity in vitiligo. J Am Acad Dermatol 1992; 26:693.
  59. Tu C, Zhao D, Lin X. Levels of neuropeptide-Y in the plasma and skin tissue fluids of patients with vitiligo. J Dermatol Sci 2001; 27:178.
  60. Gauthier Y, Cario-Andre M, Lepreux S, et al. Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. Br J Dermatol 2003; 148:95.
  61. Taïeb A, Picardo M, VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20:27.
  62. Cohen BE, Mu EW, Orlow SJ. Comparison of Childhood Vitiligo Presenting with or without Associated Halo Nevi. Pediatr Dermatol 2016; 33:44.
  63. Marinho Fde S, Cirino PV, Fernandes NC. Clinical epidemiological profile of vitiligo in children and adolescents. An Bras Dermatol 2013; 88:1026.
  64. Ezzedine K, Diallo A, Léauté-Labrèze C, et al. Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients. Br J Dermatol 2011; 165:44.
  65. Silverberg NB. Pediatric vitiligo. Pediatr Clin North Am 2014; 61:347.
  66. Ezzedine K, Le Thuaut A, Jouary T, et al. Latent class analysis of a series of 717 patients with vitiligo allows the identification of two clinical subtypes. Pigment Cell Melanoma Res 2014; 27:134.
  67. Ezzedine K, Mahé A, van Geel N, et al. Hypochromic vitiligo: delineation of a new entity. Br J Dermatol 2015; 172:716.
  68. de Barros JC, Machado Filho CD, Abreu LC, et al. A study of clinical profiles of vitiligo in different ages: an analysis of 669 outpatients. Int J Dermatol 2014; 53:842.
  69. van Geel N, Speeckaert R, Taieb A, et al. Koebner's phenomenon in vitiligo: European position paper. Pigment Cell Melanoma Res 2011; 24:564.
  70. Ciardella AP, Horsley MB, Brown DM. Hypopigmentary fundus changes seen with cutaneous vitiligo. Arch Ophthalmol 2007; 125:576.
  71. Vingerling JR, Owens S, van der Meijden WI, et al. Cutaneous vitiligo associated with choroidal hypopigmentation. Eye (Lond) 2004; 18:939.
  72. Albert DM, Wagoner MD, Pruett RC, et al. Vitiligo and disorders of the retinal pigment epithelium. Br J Ophthalmol 1983; 67:153.
  73. Cowan CL Jr, Halder RM, Grimes PE, et al. Ocular disturbances in vitiligo. J Am Acad Dermatol 1986; 15:17.
  74. Albert DM, Nordlund JJ, Lerner AB. Ocular abnormalities occurring with vitiligo. Ophthalmology 1979; 86:1145.
  75. Gey A, Diallo A, Seneschal J, et al. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms. Br J Dermatol 2013; 168:756.
  76. Sheth VM, Guo Y, Qureshi AA. Comorbidities associated with vitiligo: a ten-year retrospective study. Dermatology 2013; 227:311.
  77. Vrijman C, Kroon MW, Limpens J, et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol 2012; 167:1224.
  78. Gill L, Zarbo A, Isedeh P, et al. Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study. J Am Acad Dermatol 2016; 74:295.
  79. Chen YT, Chen YJ, Hwang CY, et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol 2015; 29:1362.
  80. Collins SM, Dominguez M, Ilmarinen T, et al. Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Br J Dermatol 2006; 154:1088.
  81. Millar S, Carson D. Clinical phenotypes of autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy seen in the Northern Ireland paediatric population over the last 30 years. Ulster Med J 2012; 81:118.
  82. Andrade A, Pithon M. Alezzandrini syndrome: report of a sixth clinical case. Dermatology 2011; 222:8.
  84. Niikawa N, Matsuura N, Fukushima Y, et al. Kabuki make-up syndrome: a syndrome of mental retardation, unusual facies, large and protruding ears, and postnatal growth deficiency. J Pediatr 1981; 99:565.
  85. Ming JE, Russell KL, McDonald-McGinn DM, Zackai EH. Autoimmune disorders in Kabuki syndrome. Am J Med Genet A 2005; 132A:260.
  86. Stagi S, Gulino AV, Lapi E, Rigante D. Epigenetic control of the immune system: a lesson from Kabuki syndrome. Immunol Res 2016; 64:345.
  87. Zannolli R, Buoni S, Macucci F, et al. Kabuki syndrome with trichrome vitiligo, ectodermal defect and hypogammaglobulinemia A and G. Brain Dev 2007; 29:373.
  88. Cho EA, Lee MA, Kang H, et al. Vitiligo-like Depigmentation Associated with Metastatic Melanoma of an Unknown Origin. Ann Dermatol 2009; 21:178.
  89. Onsun N, Büyükbabani N, Ummetoğlu O, Cebeci F. Do we have to pay more attention to vitiligo patients? Peculiar histopathological features of primary cutaneous melanoma preceded by vitiligo. J Dermatol 2009; 36:612.
  90. Redondo P, Del Olmo J. Images in clinical medicine. Vitiligo and cutaneous melanoma. N Engl J Med 2008; 359:e3.
  91. Quaglino P, Marenco F, Osella-Abate S, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol 2010; 21:409.
  92. Talsania N, Lamb B, Bewley A. Vitiligo is more than skin deep: a survey of members of the Vitiligo Society. Clin Exp Dermatol 2010; 35:736.
  93. Pahwa P, Mehta M, Khaitan BK, et al. The psychosocial impact of vitiligo in Indian patients. Indian J Dermatol Venereol Leprol 2013; 79:679.
  94. Thompson AR, Clarke SA, Newell RJ, et al. Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo. Br J Dermatol 2010; 163:481.
  95. Linthorst Homan MW, Spuls PI, de Korte J, et al. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol 2009; 61:411.
  96. Lin X, Tang LY, Fu WW, Kang KF. Childhood vitiligo in China: clinical profiles and immunological findings in 620 cases. Am J Clin Dermatol 2011; 12:277.
  97. Linthorst Homan MW, de Korte J, Grootenhuis MA, et al. Impact of childhood vitiligo on adult life. Br J Dermatol 2008; 159:915.
  98. Ezzedine K, Silverberg N. A Practical Approach to the Diagnosis and Treatment of Vitiligo in Children. Pediatrics 2016; 138.
  99. Thatte SS, Khopkar US. The utility of dermoscopy in the diagnosis of evolving lesions of vitiligo. Indian J Dermatol Venereol Leprol 2014; 80:505.
  100. Meng R, Zhao G, Cai RK, et al. Application of polarized light dermoscopy in the early diagnosis of vitiligo and its differential diagnosis from other depigmented diseases. Chinese J Dermatol 2009; 42:810.
  101. Montes LF, Abulafia J, Wilborn WH, et al. Value of histopathology in vitiligo. Int J Dermatol 2003; 42:57.
  102. Yadav AK, Singh P, Khunger N. Clinicopathologic Analysis of Stable and Unstable Vitiligo: A Study of 66 Cases. Am J Dermatopathol 2016; 38:608.
  103. van Geel NA, Mollet IG, De Schepper S, et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res 2010; 23:375.
  104. Daneshpazhooh M, Mostofizadeh G M, Behjati J, et al. Anti-thyroid peroxidase antibody and vitiligo: a controlled study. BMC Dermatol 2006; 6:3.
  105. Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, et al. Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol 2005; 53:220.
  106. Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmun 2005; 25 Suppl:63.
  107. Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008; 159:1051.
  108. Bilgiç Ö, Bilgiç A. Possible atomoxetine-induced vitiligo: a case report. Atten Defic Hyperact Disord 2015; 7:179.
  109. Doğan Z, Özdemir P, Ekşioğlu M, Filik L. Relationship between Helicobacter pylori infection and vitiligo: a prospective study. Am J Clin Dermatol 2014; 15:457.
  110. Craiglow BG, King BA. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatol 2015; 151:1110.
  111. Ezzedine K, Amazan E, Séneschal J, et al. Follicular vitiligo: a new form of vitiligo. Pigment Cell Melanoma Res 2012; 25:527.
  112. Kim SK, Kang HY, Lee ES, Kim YC. Clinical and histopathologic characteristics of nevus depigmentosus. J Am Acad Dermatol 2006; 55:423.
  113. Lee HS, Chun YS, Hann SK. Nevus depigmentosus: clinical features and histopathologic characteristics in 67 patients. J Am Acad Dermatol 1999; 40:21.
  114. Shin MK, Jeong KH, Oh IH, et al. Clinical features of idiopathic guttate hypomelanosis in 646 subjects and association with other aspects of photoaging. Int J Dermatol 2011; 50:798.
  115. Weyant GW, Chung CG, Helm KF. Halo nevus: review of the literature and clinicopathologic findings. Int J Dermatol 2015; 54:e433.
  116. Ghosh S, Mukhopadhyay S. Chemical leucoderma: a clinico-aetiological study of 864 cases in the perspective of a developing country. Br J Dermatol 2009; 160:40.
  117. Ghasri P, Gattu S, Saedi N, Ganesan AK. Chemical leukoderma after the application of a transdermal methylphenidate patch. J Am Acad Dermatol 2012; 66:e237.
  118. Tanemura A, Yang L, Yang F, et al. An immune pathological and ultrastructural skin analysis for rhododenol-induced leukoderma patients. J Dermatol Sci 2015; 77:185.
  119. Nishioka M, Tanemura A, Yang L, et al. Possible involvement of CCR4+ CD8+ T cells and elevated plasma CCL22 and CCL17 in patients with rhododenol-induced leukoderma. J Dermatol Sci 2015; 77:188.
  120. Jalalat SZ, Cohen PR. Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation. Dermatol Online J 2013; 19:20020.
  121. Llamas-Velasco M, Fraga J, Kutzner H, et al. Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study. J Cutan Pathol 2014; 41:417.
  122. Arya V, Bansal M, Girard L, et al. Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review. Case Rep Dermatol 2010; 2:156.
  123. Oiso N, Sato M, Kawada A. Vitiligo after combination therapy of pegylated interferon-α-2a, ribavirin and vitamin D in a patient with chronic hepatitis C. J Dermatol 2013; 40:772.
  124. Tolkachjov SN, Comfere NI. Hypopigmented mycosis fungoides: a clinical mimicker of vitiligo. J Drugs Dermatol 2015; 14:193.
  125. Furlan FC, Sanches JA. Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology. An Bras Dermatol 2013; 88:954.